Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review

P Ozieranski, L Martinon, PA Jachiet, S Mulinari - BMJ open, 2021 - bmjopen.bmj.com
Objectives To examine the accessibility and quality of drug company payment data in
Europe. Design Comparative policy review of payment data in countries with different …

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

P Ozieranski, H Saito, E Rickard, S Mulinari… - Globalization and …, 2023 - Springer
Background Self-regulation of payment disclosure by pharmaceutical industry trade groups
is a major global approach to increasing transparency of financial relationships between …

A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups

E Rickard, P Ozieranski - PloS one, 2021 - journals.plos.org
Our objective was to examine conflicts of interest between the UK's health-focused All-Party
Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018 …

Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs

S Mulinari, A Vilhelmsson, E Rickard, P Ozieranski - PLoS One, 2020 - journals.plos.org
Background Many patient organisations collaborate with drug companies, resulting in
concerns about commercial agendas influencing patient advocacy. We contribute to an …

[HTML][HTML] Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: an observational study

F Moriarty, J Larkin, T Fahey - Health Policy, 2021 - Elsevier
Background: The pharmaceutical industry makes large numbers of payments to healthcare
organisations (HCOs) and healthcare professionals (HCPs). Ireland has a large …

A 'patient–industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding

P Ozieranski, JG Pitter, E Rickard… - Sociology of health & …, 2022 - Wiley Online Library
We examined the minimum extent of dependency of UK patient organisations on
pharmaceutical industry funding using drug company disclosure reports and patient …

[HTML][HTML] Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: an observational study

J Larkin, S Mulinari, P Ozieranski, K Lynch… - Health Policy and …, 2024 - Elsevier
Objective Medical device industry payments to healthcare organisations (HCOs) can create
conflicts of interest which can undermine patient care. One way of addressing this concern is …

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)

P Ozieranski, M Csanádi, E Rickard, S Mulinari - BMJ open, 2020 - bmjopen.bmj.com
Objectives To examine the under-reporting of pharmaceutical company payments to patient
organisations by donors and recipients. Design Comparative descriptive analysis of …

Disclosure of pharmaceutical industry funding of patient organisations in Nordic countries: can industry self-regulation deliver on its transparency promise?

D Pashley, P Ozieranski… - International Journal of …, 2022 - journals.sagepub.com
Pharmaceutical companies regularly fund patient organizations. It is important for patient
organizations' credibility that there be transparency regarding this financial support. In …

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis

E Rickard, E Carmel, P Ozieranski - BMJ open, 2023 - bmjopen.bmj.com
Objectives To examine the characteristics of pharmaceutical payments to healthcare and
patient organisations in the four UK countries. Compare companies spending the most; …